Vimarsana
Biggest News Aggregation in the World

Page 18 - Cochlear Limited News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Cochlear Limited. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Cochlear Limited Today - Breaking & Trending Today

6 ASX 200 shares with ex-dividend dates in the next week - Vimarsana News

6 ASX 200 shares with ex-dividend dates in the next week

These six S&P/ASX 200 Index (ASX: XJO) shares will soon be going ex-dividend and allocating their dividends to shareholders.

Sensorion Reports Full-Year 2022 Financial Results and Business Update - Vimarsana News

Sensorion Reports Full-Year 2022 Financial Results and Business Update

CTA filing for OTOF-GT planned for Q2 2023 Presented new preclinical data supporting continued progress of OTOF-GT, and potential for safe and efficient clinical translation of gene therapy

Sensorion Discloses No Exposure To Silicon Valley Bank Closure - Vimarsana News

Sensorion Discloses No Exposure To Silicon Valley Bank Closure

MONTPELLIER, France--(BUSINESS WIRE)--Regulatory News:Sensorion (FR0012596468 – ALSEN) a pioneering clinical-stage biotechnology company which specializes in gene therapies in the ear, has learned that Silicon Valley Bank (SVB) has been closed by the California Department of Financial Protection and Innovation, whic...

Sensorion Announces Agenda For R&D Day Showcasing Gene Therapy For Inner Ear Disease - Vimarsana News

Sensorion Announces Agenda For R&D Day Showcasing Gene Therapy For Inner Ear Disease

Thursday April 6, 2023, at 8am EDT, 2pm CEST Regulatory News: Sensorion, (FR0012596468 ALSEN) a pioneering clinical-stage biotechnology company, specialising in the development of novel therapies

Sensorion Discloses No Exposure To Silicon Valley Bank Closure - Vimarsana News

Sensorion Discloses No Exposure To Silicon Valley Bank Closure

Regulatory News: Sensorion (FR0012596468 ALSEN) a pioneering clinical-stage biotechnology company which specializes in gene therapies in the ear, has learned that Silicon Valley Bank (SVB) has been